Banner

Lung Cancer Drugs Global Market Report 2022 – By Disease Type (Small Cell Lung Cancer: SCLC), Non-Small Cell Lung Cancer: NSCLC)), By End User (Hospitals, Clinics), By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 175 | Published : October 2022 | SKU CODE : 7195 | Delivery Time: 2-3 business days | Format :


The lung cancer drugs market consists of sales of lung cancer drugs. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer that grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa, and others and are used in various sectors such as hospitals, clinics, and others.

The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides lung cancer drugs market statistics, including lung cancer drugs industry global market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global lung cancer drugs market grew from $28.41 billion in 2021 to $33.04 billion in 2022 at a compound annual growth rate (CAGR) of 16.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The lung cancer drugs market is expected to grow to $52.27 billion in 2026 at a CAGR of 12.1%.

The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in the prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the World Health Organization report, cancer led to around 10 million deaths in 2020, out of which, lung cancer was responsible for the largest number of deaths (1.80 million deaths).

The increasing use of biologics and targeted therapies is a major restraint for the lung cancer market. This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body. Chemical drugs lack cell specificity, i.e., they destroy even the normal body cells along with cancer-infected cells. While biologic drugs are highly targeted and work on cancer-infected cells only. Biologic drugs are also very efficient with no side effects. Clinical studies have also found that the probability of success of biological drugs is much higher than that of conventional chemical drugs. For example, Cetuximab, Gefitinib, and Afatinib are lung cancer biologic drugs that specifically target only the muted form of tumours and do not destroy the normal body cells.

Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention, and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co. and is sold under the brand name Keytruda.

The FDA's guidelines for lung cancer drugs are mentioned within the Code for Federal Regulations (CFR) title number 21 under part 312, which contains sub-parts from 'A' to 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as lung cancer. The subpart 'E' also includes guidelines for monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All drug manufacturers are required to abide by these regulations by the FDA. Hence, regulations such as these would also keep a check on manufacturers of lung cancer drugs.

Major players in the lung cancer market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation.

North America is the largest region in the lung cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global lung cancer drugs market is segmented -

1) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)

2) By End User: Hospitals, Clinics, Others

3) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Others

    Table Of Contents

    1. Executive Summary

    2. Lung Cancer Drugs Market Characteristics

    3. Lung Cancer Drugs Market Trends And Strategies

    4. Lung Cancer Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Lung Cancer Drugs Market

    4.2 Ukraine-Russia War Impact On Lung Cancer Drugs Market

    4.3 Impact Of High Inflation On Lung Cancer Drugs Market

    5. Lung Cancer Drugs Market Size And Growth

    5.1. Global Lung Cancer Drugs Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Lung Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Lung Cancer Drugs Market Segmentation

    6.1. Global Lung Cancer Drugs Market, Segmentation  By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Small cell lung cancer (SCLC)

    Non-small cell lung cancer (NSCLC)

    6.2. Global Lung Cancer Drugs Market, Segmentation  By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

     Hospitals

    Clinics

    Others

    6.3. Global Lung Cancer Drugs Market, Segmentation  By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Gemzar

    Paraplatin

    Taxotere

    Navelbine

    Avastin

    Tarceva

    Iressa

    Others  

    7. Lung Cancer Drugs Market Regional And Country Analysis

    7.1. Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Lung Cancer Drugs Market  

    8.1. Asia-Pacific Lung Cancer Drugs Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.4. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Lung Cancer Drugs Market  

    9.1. China Lung Cancer Drugs Market Overview  

    9.2. China Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.4. China Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Lung Cancer Drugs Market  

    10.1. India Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.3. India Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Lung Cancer Drugs Market  

    11.1. Japan Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.3. Japan Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Lung Cancer Drugs Market  

    12.1. Australia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.3. Australia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Lung Cancer Drugs Market  

    13.1. Indonesia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.3. Indonesia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Lung Cancer Drugs Market  

    14.1. South Korea Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.3. South Korea Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Lung Cancer Drugs Market  

    15.1. Western Europe Lung Cancer Drugs Market Overview

    15.2. Western Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.4. Western Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Lung Cancer Drugs Market  

    16.1. UK Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.3. UK Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Lung Cancer Drugs Market  

    17.1. Germany Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.3. Germany Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Lung Cancer Drugs Market  

    18.5. France Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.6. France Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.7. France Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Lung Cancer Drugs Market  

    19.1. Eastern Europe Lung Cancer Drugs Market Overview

    19.2. Eastern Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.4. Eastern Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Lung Cancer Drugs Market  

    20.1. Russia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.3. Russia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Lung Cancer Drugs Market  

    21.1. North America Lung Cancer Drugs Market Overview

    21.2. North America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.4. North America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Lung Cancer Drugs Market  

    22.1. USA Lung Cancer Drugs Market Overview

    22.2. USA Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.4. USA Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Lung Cancer Drugs Market  

    23.1. South America Lung Cancer Drugs Market Overview

    23.2. South America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.4. South America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Lung Cancer Drugs Market  

    24.1. Brazil Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.3. Brazil Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Lung Cancer Drugs Market  

    25.1. Middle East Lung Cancer Drugs Market Overview

    25.2. Middle East Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.4. Middle East Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Lung Cancer Drugs Market  

    26.1. Africa Lung Cancer Drugs Market Overview

    26.2. Africa Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.4. Africa Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Lung Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Lung Cancer Drugs Market Competitive Landscape

    27.2. Lung Cancer Drugs Market Company Profiles

    27.2.1. Bristol-Myers Squibb Company

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Merck & Co.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. F. Hoffmann-La Roche Ltd

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novartis AG

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Pfizer Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Lung Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Lung Cancer Drugs Market

    30. Lung Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Lung Cancer Drugs Market, Segmentation  By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Lung Cancer Drugs Market, Segmentation  By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Lung Cancer Drugs Market, Segmentation  By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 47: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 48: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 49: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 50: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 51: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 52: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 53: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 54: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 55: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 56: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 57: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 58: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 59: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 60: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 61: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 62: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 63: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 64: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 65: Bristol-Myers Squibb Company Financial Performance
  • Table 66: Merck & Co. Financial Performance
  • Table 67: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 68: Novartis AG Financial Performance
  • Table 69: Pfizer Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Lung Cancer Drugs Market, Segmentation  By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Lung Cancer Drugs Market, Segmentation  By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Lung Cancer Drugs Market, Segmentation  By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 47: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 48: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 49: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 50: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 51: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 52: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 53: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 54: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 55: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 56: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 57: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 58: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 59: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 60: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 61: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 62: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 63: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 64: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 65: Bristol-Myers Squibb Company Financial Performance
  • Figure 66: Merck & Co. Financial Performance
  • Figure 67: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 68: Novartis AG Financial Performance
  • Figure 69: Pfizer Inc. Financial Performance
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the anti-parkinson drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth
Best Prospects in the Global Hormonal Contraceptives Market and Strategies for Growth – Includes Hormonal Contraceptives Market Share
Take Up Global Biosimilars Market Opportunities With Clear Industry Data – Includes Biosimilars Market Size
Take Up Global Nucleic Acid Based Gene Therapy Market Opportunities with Clear Industry Data – Includes Nucleic Acid Based Gene Therapy Market Size
Global Enzyme Inhibitor Market Overview And Prospects – Includes Enzyme Inhibitor Market Share
Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Vaccines Global Market Report 2022 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Cancer Type (Prostate, Cervical, Colorectal, Throat), By End-User (Cancer Treatment Centers, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Thyroid Cancer Drugs Global Market Report 2022 – By Drug Type (Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Others), By End Users (Hospitals, Oncology Clinics, Research Organizations, Others), By Type (Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Prostate Cancer Drugs Global Market Report 2022 – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy , Immunotherapy, Targeted Therapy), By End User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Skin Cancer Drugs Global Market Report 2022 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By End Users (Hospitals, Cancer Research Centers, Clinics), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Blood Cancer Drugs Global Market Report 2022 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituaxan/Mabthera: Rituximab), Gleevac/Glivec: Imatinib), Revlimid: Lenalidomide), Velcade: Bortezomib), Tasigna: Nilotinib), Pomalyst: Pomalidomide), Vidaza: Azacitidine), Kyprolis: Carfilzomib), Adcetris: Brentuximab Vedotin)), By Treatment Approaches (Key Findings, Chemotherapeutic, Mabs/Targeted Therapies, Immunotherapeutic) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Bladder Cancer Drugs Global Market Report 2022 – By Type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer), By Application (Low-Grade Tumors, High-Grade Tumors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Pancreatic Cancer Drugs Global Market Report 2022 – By Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), By End User (Hospitals, Clinics, Others), By Drugs (Afinitor, Erlotinib, Hydrochloride Everolimus, 5-FU, Flurouracil, Gemcitanine, Abraxane) – Market Size, Trends, And Global Forecast 2022-2026
View Report